CKD-MBD
Newsletter #5 (1), 2016
News

As of December 2015 the number of members of our WG is 324.

Two scientific activities have been organized in recent months:

- In Leuven (Belgium) on 21st -22nd of September, 2015, the meeting “UPDATE IN VASCULAR CALCIFICATION AND CALCIPHYLAXIS (See program at: http://www.era-edtaworkinggroups.org/en-US/group/ckd-mbd/past-meetings-3#sthash.JGSfRxjd.dpuf) was attended by 110 participants. The scientific quality was high and the local organization (by Dr. Pieter Evenepoel) was perfect.
- In Milan (Italy) on  5th of December, 2015, the 3rd WORKSHOP of CKD-MBD ERA-EDTA Working Group, (See program at: http://www.era-edtaworkinggroups.org/en-US/group/ckd-mbd/past-meetings-3#sthash.JGSfRxjd.dpuf) was attended by 300 participants. Importantly, for the first time a larger space was given to young researchers , from east and west Europe who were invited to present original research during a poster session. Five works were presented orally (15 minutes) and one (Dr. Ciceri P. from Milan – Italy) was awarded as the best.

ERA-EDTA is represented by two board members in the KDIGO committee that is preparing an update of the 2009 guidelines on CKD-MBD

Thanks to Jordi Bover, the term CKD-MBD is now available on Wikipedia. This large global resource now recognizes this entity too as of relevance for a wide audience.

Current and upcoming activities
Publications:

A review paper, partly narrative and partly systematic in collaboration with Cochrane Group, on the role of Magnesium in renal patients is currently under revision in an important journal.
During the meeting in Leuven a questionnaire on CUA perception has been realized, whose results became part of a paper recently accepted for publication on NDT.
In cooperation with the ERA-EDTA working group on Renal Nutrition (ERN), two overview papers are being prepared. The first deals with Vitamin D Status and its Relationship to Muscle Health and Frailty in Chronic Kidney Disease.  The second paper covers the relevance of diet and modifications thereof in phosphate homeostasis and potential toxicity.

Cooperation: The CKD-MBD working group is cooperating with:
- the European Society of Pediatric Nephrology in order to develop common specific lines of clinical research in the field of CKD-MBD, spanning both pediatric and adult nephrology.
- The Japanese Society of Nephrology, (JSN) by being represented at each other meetings, share continental experience. In addition, JSN will benefit of European experience in establishing a Working Group on CKD-MBD.
- The European Renal Nutrition (ERN) working group in combining forces on scientific topics at the boundaries of MBD and the nutritional impact on that.

WG Activities:
A
The final program of the Milan Meeting (Dec 5th 2015) is available at: http://www.ndt-educational.org/cme2015/FINAL_PROGRAM_3th_WORKSHOP_2015.pdf . The slides of the following presentations are also available:
  1
THE ROLE OF VITAMIN K IN CKD V Brandenburg (Germany) (pdf file)
  2
VASCULAR CALCIFICATION: BEYOND PHOSPHATE M Cozzolino (Italy) (pdf file)
  3
CaSR AND THE VASCULATURE Z Massy (France) (pdf file)
  4
CIRCULATING BIOMARKERS OF BONE DISEASE IN CKD S Mazzaferro (Italy) (pdf file)
  5
LECTURE: VITAMIN D IN KIDNEY TRANSPLANTATION P Evenepoel (Belgium)
B Arguments discussed during the Meeting in Leuven can be seen at: http://www.era-edta.org/ckdmbd/flyer_CME_Leuven_2015.pdf.  Slides are also available of the following presentations:
  1 Is vascular calcification clinically relevant in CKD?
    a. Conductance vs resistant vessels? Intima vs media calcification? (D. Goldsmith)
  2 What’s new in the pathophysiology of uremic VC?
    a. The kidney-bone-vascular axis (P. Urena Torres) (pdf file)
    b. Premature aging and VC in CKD (P. Stenvinkel)
  3 Who, when and how to scren for VC in CKD? (J. Bover) (pdf file)
  4 Is VC modifiable in CKD?
    a. Targeting bone: treat the bone to cure the vessels (S. Mazzaferro) (pdf file)
    b. Targeting PTH (P. Evenepoel)
    c. Targeting phosphate (M. Cozzolino) (pdf file)
    d. Vitamin K, Matrix-gla protein and VC (J. Floege)
C Calciphylaxis registry. The Internet site (www. calciphylaxis.net) is now available in several languages for local uses. On December 2015 the first patient (from Germany) has been added in the Registry which is thus functioning.
D Bone Biopsy Registry. this bone-biopsy network aims at joining nephrologists, endocrinologists and pathologists (Coordinator: Pieter Evenepoel) to collect the largest possible bone samples to be examined homogeneously, in order to improve knowledge on the role of bone in systemic disease.
E MBD risk prediction score in CKD. Dr. Vervloet and Massy are aiming at evaluating data from large registries to develop a score capable of predicting risk attributable to MBD.
Next appointments
A
On May 21st-24th, 2016, during the ERA-EDTA Congress in Vienna the following CME course is organized by the WG: “New insights into CKD-MBD.” The titles and speakers are:
  a. Will klotho and FGF23 make you change your clinical practice? (M. Vervloet)
  b. Alkaline Phosphatase (J. Bover)
  c. Phosphate (M. Cozzolino)
  d What do observational and intervention studies teach us? (D. Goldsmith)
  e. PTH resistance in CKD (P. Evenpoel)
  f. What is the role of bone biopsy and bone markers (P. Urena Torres)
B
On September 2016, in Amsterdam, Dr, Vervloet and Dr Massy will host the meeting “Bone in CKD”. Also this will be a CME course with the following preliminary program:
  a. Uremic toxicity and CKD bone Masa Fukagawa
  b. Bone biopsy: Procedure, indications and histomorphometry anno 2016 Pieter Evenepoel
  c. Changing Bone Patterns with Progression of Chronic Kidney Disease Ziad Massy
  d. Interpretation of DEXA Micro CT in CKD and dialysis Marie Helene Lafage
  e. Meet The Expert” Sessions are in the program
  f. Bone histology based treatment Patrick D’Haese and Pieter Evenepoel
  g. Evaluation of fracture (risk) in CKD Martine Cohen-Solal and Pablo Urena
  h. Vitamin D and Osteoporosis in CKD Paul Lips
  i. Current treatments: bisphosphonates, estrogen, vitamin D Calcium and Raloxifen Mario Cozzolino
  l. Positioning novel biologicals in CKD Sandro Mazzaferro
C The fourth workshop on CKD-MBD is already scheduled to be held in Milan, December 2016
CKD-MBD related publications in NDT and CKJ
http://era-edta.org/ckdmbd/Newsletter_5_3_2_2016_FINAL.pdf
As a contribution of ERA-EDTA communication team, we are again reporting on the most recent papers published on the journals of our society and dealing with CKD-MBD. The content of this third group of papers is reported in a separate link
NEWS on Clinical Kidney Journal (CKJ)
CKJ has been accepted by DOAJ (Directory of Open Access Journals) for inclusion in their list of open access journals. DOAJ is an online resource that indexes and provides access to high quality, open access, peer-reviewed journals. This will increase exposure of our journal content!

The possibility of submitting papers to CKJ free of charge submission fees,
continues up to the end of the year! Run to submit original papers!